Research Analysts’ Weekly Ratings Changes for Immuneering (IMRX)

Immuneering (NASDAQ: IMRX) has recently received a number of price target changes and ratings updates:

• 12/22/2025 – Immuneering had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/20/2025 – Immuneering was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/15/2025 – Immuneering had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Immuneering had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Immuneering had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Immuneering had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/15/2025 – Immuneering was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/13/2025 – Immuneering had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
• 10/31/2025 – Immuneering was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating.
• 10/31/2025 – Immuneering is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $15.00 price target on the stock.

Insider Activity at Immuneering

In other Immuneering news, Director Peter Feinberg bought 7,500 shares of the business’s stock in a transaction dated Friday, October 3rd. The shares were acquired at an average cost of $6.67 per share, with a total value of $50,025.00. Following the acquisition, the director directly owned 156,766 shares of the company’s stock, valued at $1,045,629.22. The trade was a 5.02% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders bought a total of 15,800 shares of company stock worth $107,854 in the last 90 days. 22.90% of the stock is currently owned by insiders.

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.